www.hivandhepatitis.com

International AIDS Society Prioritizes HIV Cure [VIDEO]

The International AIDS Society (IAS) has designated research towards a cure for HIV/AIDS as one of its top priorities. The spring IAS established a global working group focusing on HIV reservoirs and their eradication -- a key element in the search for a cure for HIV/AIDS.

Nobel Laureate and IAS president-elect Francoise Barré-Sinoussi recently spoke with HIVandHepatitis.com about the new group, some promising areas of exploration, and the need for more funding to bring this research to fruition.

Read more:

18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)

HIV/AIDS Articles

• Can Lowering Community Viral Load Decrease New HIV Infections?
• Positive Pulse: Expert Commentaries From CROI 2011*
• HPV and Anal Cancer Research at CROI 2011
• HIV Enters and Injures Brain Early
• Vitamin D May Reduce Tenofovir-related Bone Loss
• Do Black Patients Respond Less Well to Antiretroviral Therapy?
• Immediate ART Improves Survival for HIV+ People with TB
• Reduced Limb Muscle, More Belly Fat Linked to Higher Mortality
• Studies Shed Further Light on Cardiovascular Disease among People with HIV
• Low Vitamin D Levels Less Likely with Rilpivirine than Efavirenz
• Longer Preventive Therapy, More Drugs Reduce Risk of Mother-to-Child HIV Transmission
• Experimental Integrase Inhibitor Dolutegravir Looks Promising for People with Resistant HIV
• Is Bone Loss Related to Immune Reconstitution in People on ART?
• New Tenofovir Pro-drug GS-7340 Looks Good in Early Study
• 5 Drugs No Better than 3 for Treatment of Primary HIV Infection
• Long-term Benefits of Circumcision for HIV Prevention
• No More Science Fiction -- HIV Gene Therapy Delivers
• Once-daily Raltegravir Found Less Effective than Twice-Daily Dosing
• HIV Attachment Inhibitor BMS-663068 Shows Good Activity in Phase 2a Trial
• Researchers Report Further Findings from iPrEx PrEP Trial
• Safety and Acceptability of Tenofovir Gel and Tablets for Pre-exposure Prevention
• FDA Safety Review Does Not Find Abacavir-Heart Attack Link
• International AIDS Society Launches International HIV Cure Working Group

HIV/HCV and HIV/HBV Coinfection Articles

• HCV Re-infection Common among HIV+ Gay Men in Amsterdam
• HIV/HCV Coinfected People Have Higher Risk of Bone Loss
• Acute Hepatitis C Treatment for HIV/HCV Coinfected People
• Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir
• Liver Fibrosis Raises Risk of Kidney Impairment in HIV/HBV Coinfected Patients on Tenofovir
• Little Overlap of Sexually Transmitted HCV between U.S. and Europe
• More Liver-related Death for HIV/HBV than HIV/HCV Coinfection in MACS Cohort
• Telaprevir Improves Treatment Outcomes for HIV/HCV Coinfected People

Library of Slides and Posters

• Success of Test and Treat in San Francisco? Reduced Time to VirologicSuppression, Decreased Community Viral Load, and Fewer New HIV Infections, 2004 to 2009
  M Das and others. CROI 2011.
• Use of Community Viral Load as Population-Based Biomarker of HIV „Ÿ Washington, DC, 2004 . 2008
  A Castel and others. CROI 2011.
• Disparities in Community Viral Load among HIV Infected Persons in NYC
  F Laraque and others. CROI 2011.
• HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors
  M Freiberg and others. CROI 2011.
• Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members
  D Klein and others. CROI 2011.
• No Association of Myocardial Infarction with Abacavir Use: Findings of an FDA Meta-analysis
  X Ding and others. CROI 2011.
• Raltegravir (RAL) Demonstrates Durable Virologic Suppression and Superior Immunologic Response with a Favorable Metabolic Profile Through 3 Years Treatment (Tx): 156 Week (Wk) Results from STARTMRK
  J Rockstroh and others. CROI 2011.
• ARIEL: 24-week safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years
  A Violari and others. CROI 2011.
• Pharmacokinetic Parameters of Once-Daily TMC278 Following Administration of Efavirenz in Healthy Volunteers
  H Crauwels and others. CROI 2011.
• Lipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 data from the randomized, double-blind, Phase III ECHO and THRIVE trials
  J Arribas and others. CROI 2011.
• Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks
  A Mills and others. CROI 2011.
• Change in Vitamin D Levels Smaller and Risk of Development of Severe Vitamin D Deficiency Lower Among HIV-1-Infected, Treatment-naïve Adults Receiving TMC278 Compared with Efavirenz: 48-week Results from the Phase III ECHO Trial
  D Wohl and others. CROI 2011.
• GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir DisoproxilFumarateDuring 14 Days of Monotherapyin HIV-1 Infected Subjects
  A Diamond and others. CROI 2011.
• No Association of Myocardial Infarction with ABC Use: An FDA Meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections
  X Ding and others. CROI 2011.